Enobosarm

[silntrunin]

Came across someone selling this on Facebook which I've never really heard of so I did some quick research.

The selective androgen receptor modulator GTx-024 (enobosarm) supposedly improves lean body mass and physical function in healthy older men and postmenopausal women according to some studies done.

"GTx-024 (enobosarm; United States Adopted Names Council official generic name) is an orally bioavailable nonsteroidal SARM with tissue-selective anabolic and androgenic pharmacologic activity [22–26]. In animal studies, GTx-024 increased muscle mass and bone density while having limited effects on other androgen-responsive tissues including the prostate and seminal vesicles. In fact, prostate size was reduced at doses that increased muscle mass in intact, male rats. In a phase I study in 48 healthy 18- to 45-year-old males and 23 elderly males with truncal obesity, GTx-024 administered for 14 days increased lean body mass and had a favorable tolerability profile without clinically apparent adverse effects involving the skin or prostate (data on file). A phase II, randomized, double-blind, placebo-controlled study was conducted to evaluate the effects of GTx-024 on total lean body mass and physical function in elderly men and postmenopausal women. Secondary endpoints included safety of GTx-024, effects on fat mass, bone mineral density, blood glucose, and insulin. This study is the first to demonstrate the ability of a nonsteroidal, orally bioavailable SARM to increase lean muscle mass and improve physical function."




Looking for any feedback from those that have used it or those knowledgeable about it and opinions.

[PillarofBalance]

Never heard of it but I have a bud who works with sarms... I will see what he knows.

[FlyingDragon]

Facebook? LOL

[silntrunin]

Never heard of it but I have a bud who works with sarms... I will see what he knows.

Thanks POB. I'll be doing some more research also.

[ritch]

You sure you really need that? It sounds very experimental. If you have not maxed out on say 2-4 steroids, some slin and gh, why bother with this stuff?

Not trying to preach to you...

[silntrunin]

You sure you really need that? It sounds very experimental. If you have not maxed out on say 2-4 steroids, some slin and gh, why bother with this stuff?

Not trying to preach to you...

More interested in what it is than really using it. I'm not as active on the boards as I used to be so I miss a lot of stuff thats going on. Just wanted to get some info on it and see if it was worth trying. So far, I agree with you, not enough info to warrant trying it.

[silntrunin]

This stuff is available on Ebay.ca for 250.00 ca. but I found this doing some research.

On February 21, 2012, we announced that the FDA had placed a clinical hold on our clinical trials evaluating Capesaris ® (GTx-758), an oral nonsteroidal selective estrogen receptor alpha agonist, or ER alpha agonist, for primary (first line) androgen deprivation therapy for advanced prostate cancer and secondary (second line) hormonal treatment. A clinical hold is a notification issued by the FDA to the trial sponsor to delay a clinical trial or suspend an ongoing clinical trial. The clinical hold, which was effective as of February 17, 2012, affects our Phase II maintenance dose finding clinical trial to evaluate Capesaris ® 1000 mg and 2000 mg once-a-day doses compared to Lupron Depot ® (leuprolide acetate for depot suspension) in 164 men with advanced prostate cancer, and our Phase II loading dose finding clinical trial evaluating a 1000 mg twice-a-day dose or 1500 mg twice-a-day dose to medically castrate men with advanced prostate cancer. Additionally, the clinical hold applies to our Phase II clinical trial evaluating Capesaris ® 2000 mg once-a-day dose to determine the ability of Capesaris ® to reduce serum prostate specific antigen, or PSA, and the duration of this PSA reduction in 25 men with castration resistant prostate cancer, or CRPC, who were currently receiving androgen deprivation therapy, or ADT. The clinical hold followed our reports to the FDA of venous thromboembolic events, or blood clots, in subjects treated with Capesaris ® at the doses being studied in the trials (1000 mg and higher). There were two deaths in subjects treated with Capesaris ® and two deaths in subjects treated with Lupron Depot ® . As a result of the clinical hold, we suspended further enrollment into these three studies and notified clinical sites to discontinue treatment of subjects with Capesaris ® . Subject to further input from the FDA, we believe there may be a path forward to develop Capesaris ® at lower doses to treat men with metastatic hormone sensitive prostate cancer and men with CRPC. We plan to work with the FDA to determine the appropriate course of action, if any, to evaluate Capesaris ® in these patient populations. There can be no assurance that the FDA will allow us to further develop Capesaris ® in these or any other patient populations. "

Thinking I'll stay away from this stuff for now.